India-based BSE SME-listed pharmaceutical company Aptus Pharma Limited has delivered a significant growth performance, doubling its revenue and recording a robust increase in net profit while expanding its product portfolio to over 250 formulations across chronic, acute, and wellness segments, according to India News Net.

Established in 2010, the Mumbai-based company operates on an asset-light model through WHO-GMP certified manufacturing partners, enabling quality, scalability, and capital efficiency across competitive pharmaceutical markets.

The company's business is structured across four strategic verticals: the Rx prescription segment driving core revenues through doctor engagement; an OTC vertical focused on consumer healthcare and wellness; a Global vertical contributing through exports and related service income; and the ORBIT division, a franchise-led model targeting underpenetrated regional markets across India.

Growth is supported by a distribution network covering over 25,000 retail outlets, backed by more than 200 distributors and sub-distributors, and reinforced by relationships with over 10,000 doctors enabling sustained market penetration across multiple states.

Aptus Pharma has outlined a clear strategic roadmap targeting pan-India presence by 2030, alongside plans to expand its manufacturing capabilities to improve margins and operational control, and to build a broader global footprint through export initiatives.

The company is also exploring potential entry into the retail pharmacy chain segment, which would further integrate its commercial model and strengthen direct-to-consumer reach.

From a regional pharmaceutical player, Aptus Pharma is positioning itself as a national-level force over the next three to five years, underpinned by portfolio diversification, distribution scale, and sustained execution across its key business verticals.

Access the full report for further detail on Aptus Pharma's financial performance and expansion strategy.